

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Gentamicin Sulfate Injection, USP 80 mg/2 mL (40 mg/mL as Gentamicin) (Hospira, Inc.)

Product Code(s) PZ03380
Trade Name: Not applicable
Chemical Family: Not determined

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as antibiotic agent

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company 275 North Field Drive Lake Forest, Illinois 60045 1-800-879-3477 Pfizer Ireland Pharmaceuticals

OSG Building

Ringaskiddy, Co. Cork.

Ireland

+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: Regulated according to Regulation (EC) 1272/2008 and/or other applicable regulations.

Skin sensitizationCategory 1 - (H317)Reproductive toxicityCategory 1A - (H360D)

OSHA Classification

Hazards not otherwise classified (HNOC)

Not applicable

Hazards classified under paragraph (d)(1)(ii) of 1910.1200

Not applicable

2.2. Label elements



Signal word

Danger

Product Name Gentamicin Sulfate Injection, USP 80 mg/2 mL (40 mg/mL as Gentamicin) (Hospira, Inc.)

Revision date 13-Jun-2025 Version 5

Hazard statements H317 - May cause an allergic skin reaction

H360D - May damage the unborn child

Precautionary Statements - EU (§28, P201 - Obtain special instructions before use

1272/2008)

P202 - Do not handle until all safety precautions have been read and understood

Page 2/16

P261 - Avoid breathing dust/fume/gas/mist/vapors/spray

P272 - Contaminated work clothing should not be allowed out of the workplace

P280 - Wear protective gloves and protective clothing

P308 + P313 - IF exposed or concerned: Get medical advice/attention P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention

P363 - Wash contaminated clothing before reuse

P405 - Store locked up

P501 - Dispose of contents/container in accordance with local, regional, national, and

international regulations as applicable

P302 + P352 - IF ON SKIN: Wash with plenty of soap and water

2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients

(see Section 8).

PBT & vPvB The product does not contain any substance(s) classified as PBT or vPvB.

Endocrine Disruptor Information This product does not contain any known or suspected endocrine disruptors.

Chemical name	EU - REACH (1907/2006) - Article 59(1)	EU - REACH (1907/2006) - Endocrine
	- Candidate List of Substances of Very	Disruptor Assessment List of
	High Concern (SVHC) for Authorisation	Substances
Propylparaben	-	Endocrine disrupting properties

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH	EC No (EU	Classification	Specific	M-Factor	M-Factor
		registration	Index No)	according to	concentration		(long-term)
		number		Regulation	limit (SCL)		
				(EC) No.			
				1272/2008			
				[CLP]			
Gentamicin sulfate	4		215-778-9	Repr. Cat.1A	Not classified	No data	No data
(CAS #: 1405-41-0)				(H360D)		available	available
				Skin Sens. 1			
				(H317)			
Sodium metabisulfite	<1.0		231-673-0	Acute Tox. 4	Not classified	No data	No data

Page 3/16

Product Name Gentamicin Sulfate Injection, USP 80 mg/2 mL (40 mg/mL as Gentamicin) (Hospira, Inc.) Revision date 13-Jun-2025

vision date 13-Jun-2025 Version 5

USP			(016-063-00-2)	(H302)		available	available
(CAS #: 7681-57-4)				Eye Dam. 1 (H318)			
Sodium hydroxide (CAS #: 1310-73-2)	**	-	215-185-5 (011-002-00-6)	Skin Corr.1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5% Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%	No data available	No data available
+ Hydrochloric Acid (CAS #: 7647-01-0)	**	-	231-595-7 (017-002-00-2) (017-002-01-X)		Eye Irrit. 2 :: 10%<=C<25% Skin Corr. 1B :: C>=25% Skin Irrit. 2 :: 10%<=C<25% STOT SE 3 :: C>=10%	No data available	No data available
NonHazardous							
Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Propylparaben (CAS #: 94-13-3)	<1.0		202-307-7	Not classified	Not classified	No data available	No data available
Methyl-p-hydroxyben zoate (CAS #: 99-76-3)	<1.0		202-785-7	Not classified	Not classified	No data available	No data available
Edetate disodium (CAS #: 139-33-3)	*		205-358-3	Not classified	Not classified	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate No information available

Chemical name	Oral LD50 mg/kg		Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Gentamicin sulfate 1405-41-0	5000	No data available	No data available	No data available	No data available
Sodium metabisulfite USP 7681-57-4	1310	2000	No data available	No data available	No data available
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available
Edetate disodium 139-33-3	2000	No data available	No data available	No data available	No data available
+ Hydrochloric Acid 7647-01-0	238	5010	No data available	No data available	563.3022

This product does not contain candidate substances of very high concern at a concentration >=0.1% (Regulation (EC) No. 1907/2006 (REACH), Article 59).

Product Name Gentamicin Sulfate Injection, USP 80 mg/2 mL (40 mg/mL as Gentamicin) (Hospira, Inc.)

mg/mL as Gentamicin) (Hospira, Inc.)
Revision date 13-Jun-2025

Page 4/16 Version 5

Additional information

- * Proprietary
- ** to adjust pH
- + Substance with a Union workplace exposure limit

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for completeness.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation Remove to fresh air. Seek immediate medical attention/advice.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids.

Consult a physician.

Skin contact Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion Never give anything by mouth to an unconscious person. Wash out mouth with water. Do

not induce vomiting unless directed by medical personnel. Seek medical attention

immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and

effects

For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing MediaUse extinguishing agent suitable for type of surrounding fire.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the

chemical

Not applicable.

Hazardous combustion products Emits toxic fumes of carbon monoxide, carbon dioxide, and nitrogen oxides.

Explosion data

Sensitivity to mechanical impact No information available. **Sensitivity to static discharge** No information available.

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear.

Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

Product Name Gentamicin Sulfate Injection, USP 80 mg/2 mL (40 mg/mL as Gentamicin) (Hospira, Inc.)

Revision date 13-Jun-2025 Version 5

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be

taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean

spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sectionsSee section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Page 5/16

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Gentamicin sulfate

Pfizer OEL TWA-8 Hr: 100 µg/m³

Sodium metabisulfite USP

ACGIH TLV TWA: 5 mg/m³

Denmark TWA: 5 mg/m³;

STEL: 10 mg/m³;

PZ03380

Product Name Gentamicin Sulfate Injection, USP 80 mg/2 mL (40 mg/mL as Gentamicin) (Hospira, Inc.)

Revision date 13-Jun-2025 Vers

France 5 mg/m³ Ireland TWA: 5 mg/m³;

STEL: 15 mg/m³ (calculated;thoracic fraction);
Spain
TWA-(VLA-ED): 5 mg/m³;
Switzerland
TWA-MAK: 5 mg/m³; inhalable dust

OSHA PEL (vacated) TWA: 5 mg/m³

United Kingdom TWA: 5 mg/m³; STEL: 15 mg/m³;

Sodium hydroxide

Bulgaria

ACGIH OEL (Ceiling) 2 mg/m³
ACGIH TLV Ceiling: 2 mg/m³

Austria TWA-TMW: 2 mg/m³; inhalable fraction

STEL-KZGW: 4 mg/m³ (8 X 5 min); inhalable fraction

TWA: 2.0 mg/m³; alkaline aerosols

Czech Republic 1 mg/m³

 Denmark
 Ceiling: 2 mg/m³

 Estonia
 TWA: 1 mg/m³;

 STEL: 2 mg/m³;

 Finland
 STEL: 2 mg/m³;

 Finland
 Ceiling: 2 mg/m³;

 France
 2 mg/m³

 Hungary
 TWA-AK: 1 mg/m³;

 Ceiling Limit Value
 2 mg/m³

 Latvia
 TWA: 0.5 mg/m³;

 Poland
 TWA-NDS: 0.5 mg/m³;

STEL-NDSCh: 1 mg/m³; Romania TWA: 1 mg/m³;

 STEL: 3 mg/m³;

 Slovakia
 TWA: 2 mg/m³;

 Spain
 STEL (VLA-EC): 2 mg/m³;

Switzerland TWA-MAK: 2 mg/m³; inhalable dust STEL-KZGW: 2 mg/m³; inhalable dust

OSHA PEL TWA: 2 mg/m³

(vacated) Ceiling: 2 mg/m³

United Kingdom STEL: 2 mg/m³;

Propylparaben

Russia MAC: 10 mg/m³

Methyl-p-hydroxybenzoate

Russia MAC: 4 mg/m³

Edetate disodium
Russia MAC: 2 mg/m³

+ Hydrochloric Acid
ACGIH OEL (Ceiling) 2 ppm

ACGIH TLV

Austria

Ceiling: 2 ppm
TWA-TMW: 5 ppm;
TWA-TMW: 8 mg/m³:

STEL-KZGW: 10 ppm (8 X 5 min); STEL-KZGW: 15 mg/m³ (8 X 5 min);

Bulgaria TWA: 5 ppm;
TWA: 8.0 mg/m³;

STEL: 10 ppm; STEL: 15.0 mg/m³;

Czech Republic 8 mg/m³

Ceiling: 15 mg/m³
Denmark STEL: 5 ppm;

PZ03380

Page 6/16

Version 5

mg/mL as Gentamicin) (Hospira, Inc.) Revision date 13-Jun-2025 Version 5

	STEL: 8 mg/m³;
Estonia	TWA: 5 ppm;
	TWA: 8 mg/m³;

Product Name Gentamicin Sulfate Injection, USP 80 mg/2 mL (40

Finland

Italy MDLPS

Netherlands

STEL: 10 ppm; STEL: 15 mg/m³; TWA: 5 ppm;

Page 7/16

European Union TWA: 8 mg/m³;

STEL: 10 ppm; STEL: 15 mg/m³; STEL: 5 ppm;

STEL: 7.6 mg/m³; TWA-MAK: 2 ppm; I(2); Germany DFG

TWA-MAK: 3.0 mg/m³; I(2); Peak: 4 ppm; Peak: 6 mg/m3;

Germany TRGS TWA-AGW; 2 ppm (exposure factor 2); TWA-AGW; 3 mg/m³ (exposure factor 2);

TWA-AK: 8 mg/m³; Hungary

TWA-AK: 5 ppm; STEL-CK: 165 mg/m³; STEL-CK: 10 ppm;

Ireland TWA: 8 mg/m³; TWA: 5 ppm; STEL: 10 ppm;

STEL: 15 mg/m³; TWA: 5 ppm; TWA: 8 mg/m³; STEL: 10 ppm; STEL: 15 mg/m³;

Ceiling Limit Value 2 ppm 3.0 mg/m³

Latvia TWA: 5 ppm; TWA: 8 mg/m³; STEL: 10 ppm;

STEL: 15 mg/m³; TWA: 5 ppm; TWA: 8 mg/m³; STEL: 10 ppm;

STEL: 15 mg/m³; Poland TWA-NDS: 5 mg/m³;

STEL-NDSCh: 10 mg/m3; Romania TWA: 5 ppm;

> TWA: 8 mg/m³; STEL: 10 ppm; STEL: 15 mg/m³; MAC: 5 mg/m³

Russia Slovakia TWA: 5 ppm; TWA: 8.0 mg/m³; Ceiling: 15 mg/m3;

TWA-(VLA-ED): 5 ppm; TWA-(VLA-ED): 7.6 mg/m³; STEL (VLA-EC): 10 ppm;

STEL (VLA-EC): 15 mg/m3; Switzerland TWA-MAK: 2 ppm;

TWA-MAK: 3 mg/m³; STEL-KZGW: 4 ppm; STEL-KZGW: 6 mg/m³;

PZ03380

Spain

Product Name Gentamicin Sulfate Injection, USP 80 mg/2 mL (40 mg/mL as Gentamicin) (Hospira, Inc.)

Revision date 13- lun-2025

Revision date 13-Jun-2025 Version 5

U.S. - OSHA - Final PELs - Ceiling Limits 5 ppm 7 mg/m³

OSHA PEL Ceiling: 5 ppm Ceiling: 7 mg/m³

(vacated) Ceiling: 5 ppm (vacated) Ceiling: 7 mg/m³

United Kingdom TWA: 1 ppm; gas and aerosol mist

TWA: 2 mg/m³; gas and aerosol mist STEL: 5 ppm; gas and aerosol mist STEL: 8 mg/m³; gas and aerosol mist

Page 8/16

8.2. Exposure controls

Engineering controls Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal protective equipmentRefer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety

equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in

the workplace and specific operational processes.

Eye/face protection Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the

standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is

possible and for bulk processing operations. (Protective gloves must meet the standards in

accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection Impervious protective clothing is recommended if skin contact with drug product is possible

and for bulk processing operations. (Protective clothing must meet the standards in

accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter).

(Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10

or international equivalent.).

Thermal hazards No information available.

Environmental exposure controls No information available.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

AppearanceSolutionPhysical stateLiquid

Page 9/16

Product Name Gentamicin Sulfate Injection, USP 80 mg/2 mL (40 mg/mL as Gentamicin) (Hospira, Inc.)

Revision date 13-Jun-2025 Version 5

Color No information available Odor No information available. **Odor threshold** No information available

Values_ Property

Melting point / freezing point No data available Boiling point or initial boiling point and boiling range No data available No data available

Flammability (solid, gas)

Lower and upper explosion limit/flammability limit

Lower explosion limit No data available No data available Upper explosion limit Flash point No data available Autoignition temperature No data available

Decomposition temperature

SADT (°C) No data available

pН No data available pH (as aqueous solution) No data available Kinematic viscosity No data available **Dynamic viscosity** No data available Solubility No data available Vapor pressure No data available

Density and/or relative density No data available No data available **Bulk density** No data available **Liquid Density** Vapor density No data available

Particle characteristics

No information available **Particle Size** No information available **Particle Size Distribution**

9.2. Other information

Molecular formula Mixture Molecular weight Mixture

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No information available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to mechanical impact No information available. Sensitivity to static discharge No information available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

Hazardous polymerization Will not occur.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

Product Name Gentamicin Sulfate Injection, USP 80 mg/2 mL (40 mg/mL as Gentamicin) (Hospira, Inc.)
Revision date 13-Jun-2025

Page 10 / 16

Version 5

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Short term Accidental ingestion may cause effects similar to those seen in clinical use.

Known Clinical Effects: Adverse effects associated with therapeutic use include effects on hearing, kidney effects, blood cell changes, fever, chills, allergic skin rash. Ingestion of this material may cause

effects similar to those generally seen in clinical use of antibiotics including gastrointestinal

irritation, vomiting, transient diarrhea, nausea, and abdominal pain.

Acute toxicity

Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Serious eye damage/eye irritationBased on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Respiratory or skin sensitization Classification is based on mixture calculation methods based on component data.

STOT - single exposureBased on available data, the classification criteria are not met. **STOT - repeated exposure**Based on available data, the classification criteria are not met.

Reproductive toxicity Classification is based on mixture calculation methods based on component data.

Germ cell mutagenicity
Carcinogenicity
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Gentamicin sulfate

Rat Oral LD50 > 5000 mg/kg Rat Para-periosteal LD50 96 mg/kg Rat Intramuscular LD50 384 mg/kg

Propylparaben

Mouse Oral LD 50 6332 mg/kg

Mouse Sub-tenon injection (eye) LD 50 200 mg/kg

Methyl-p-hydroxybenzoate

Mouse Oral LD50 > 8 g/kg Rat Oral LD50 2100 mg/kg

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Edetate disodium

Rat Oral LD50 2000-2200 mg/kg

rat Ofal ED00 2000-2200 fligring				
Chemical name	Oral LD50	Dermal LD50	Inhalation LC50	
Gentamicin sulfate	> 5 g/kg (Rat)	-	-	
Sodium metabisulfite USP	= 1310 mg/kg (Rat)	> 2000 mg/kg (Rat)	-	
Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg (Rabbit)	-	
Edetate disodium	= 2 g/kg (Rat)	-	-	
+ Hydrochloric Acid	238 - 277 mg/kg (Rat)	> 5010 mg/kg (Rabbit)	= 1.68 mg/L (Rat)1 h	

PZ03380

Product Name Gentamicin Sulfate Injection, USP 80 mg/2 mL (40 mg/mL as Gentamicin) (Hospira, Inc.)

Revision date 13-Jun-2025

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not

achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

+ Hydrochloric Acid
Skin irritation Severe
Eve irritation Severe

Methyl-p-hydroxybenzoate

Skin irritation Rabbit Non-irritating Eye irritation Rabbit Slight

Skin Sensitization Guinea Pig Negative

Sodium hydroxide

Eye Irritation Rabbit Severe Skin Irritation Rabbit Severe

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Propylparaben

3 Week(s) Rat Oral 27.1 g/kg LOAEL Endocrine system

4 Week(s) Rat Oral 347.2 mg/kg LOAEL Male reproductive system

Methyl-p-hydroxybenzoate

28 Day(s) Rat Oral 250 mg/kg/day NOAEL Gastrointestinal System, Spleen, Thymus

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Gentamicin sulfate

Embryo / Fetal Development Rat Intraperitoneal 375 mg/kg/day LOAEL Developmental toxicity Prenatal & Postnatal Development Rat Subcutaneous 660 mg/kg/day LOAEL Developmental toxicity Prenatal & Postnatal Development Rat Subcutaneous 660 mg/kg/day LOAEL Neonatal toxicity,

Methyl-p-hydroxybenzoate

Embryo / Fetal Development Rabbit Oral 300 mg/kg/day NOEL Maternal toxicity, Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Gentamicin sulfate

DNA Binding Assay E. coli Negative

+ Hydrochloric Acid

Bacterial Mutagenicity (Ames) Salmonella Negative

In Vivo Micronucleus Rat Negative

Methyl-p-hydroxybenzoate

In Vivo Dominant Lethal Assay Rat Negative

Carcinogenicity None of the components of this formulation are listed as a carcinogen by IARC, NTP or

OSHA.

Sodium metabisulfite USP

IARC Group 3

+ Hydrochloric Acid

IARC Group 3

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

PZ03380

Page 11 / 16

Version 5

Product Name Gentamicin Sulfate Injection, USP 80 mg/2 mL (40 mg/mL as Gentamicin) (Hospira, Inc.)

Revision date 13-Jun-2025

Revision date 13-Jun-2025 Version 5

Page 12/16

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should

be avoided.

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Methyl-p-hydroxybenzoate

Oryzias latipes (Japanese Rice Fish) OECD LC50 96 hours 59.5 mg/L

Daphnia magna (Water Flea) ISO EC50 48 hours 11.2 mg/L

12.2. Persistence and degradability

Persistence and degradability

Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

Methyl-p-hydroxybenzoate

OECD Activated sludge Ultimate (CO2 Evolution) 89 % After 28 Day(s) Ready

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment	
+ Hydrochloric Acid	Not PBT/vPvB PBT assessment does not apply	
Sodium metabisulfite USP	Not PBT/vPvB PBT assessment does not apply	
Propylparaben	Not PBT/vPvB	
Methyl-p-hydroxybenzoate	Not PBT/vPvB	
Sodium hydroxide	Not PBT/vPvB PBT assessment does not apply	
Edetate disodium	Not PBT/vPvB PBT assessment does not apply	

12.6. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

12.7. Other adverse effects

Other adverse effects No information available.

PMT or vPvM properties Based on available data, the classification criteria are not met.

PZ03380

Page 13 / 16

Product Name Gentamicin Sulfate Injection, USP 80 mg/2 mL (40 mg/mL as Gentamicin) (Hospira, Inc.) Revision date 13-Jun-2025

evision date 13-Jun-2025 Version 5

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:
UN proper shipping name:
Transport hazard class(es):
Packing group:
Environmental Hazard(s):
Not applicable
Not applicable
Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Gentamicin sulfate

CERCLA/SARA Section 313 de minimus % Not Listed
California Proposition 65 Not Listed
EINECS 215-778-9

Sodium metabisulfite USP

CERCLA/SARA Section 313 de minimus % Not Listed
California Proposition 65 Not Listed
TSCA Present
EINECS 231-673-0
AICS Present
Standard for Uniform Scheduling of Medicines and Schedule 5

Poisons (SUSMP)

Sodium hydroxide

CERCLA/SARA Section 313 de minimus % Not Listed **Hazardous Substances RQs** 1000 lb California Proposition 65 Not Listed **TSCA** Present **EINECS** 215-185-5 **AICS** Present Standard for Uniform Scheduling of Medicines and Schedule 5 Poisons (SUSMP) Schedule 6

Propylparaben

Product Name Gentamicin Sulfate Injection, USP 80 mg/2 mL (40 mg/mL as Gentamicin) (Hospira, Inc.) Revision date 13-Jun-2025

Version 5

Page 14/16

CERCLA/SARA Section 313 de minimus % Not Listed **California Proposition 65** Not Listed **TSCA** Present **EINECS** 202-307-7 Present **AICS**

Methyl-p-hydroxybenzoate

CERCLA/SARA Section 313 de minimus % Not Listed **California Proposition 65** Not Listed **TSCA** Present 202-785-7 **EINECS AICS** Present

Edetate disodium

CERCLA/SARA Section 313 de minimus % Not Listed **California Proposition 65** Not Listed **TSCA** Present **EINECS** 205-358-3 Present **AICS**

+ Hydrochloric Acid

CERCLA/SARA Section 313 de minimus % 1.0 % **Hazardous Substances RQs** 5000 lb **California Proposition 65** Not Listed **TSCA** Present **EINECS** 231-595-7 **AICS** Present Standard for Uniform Scheduling of Medicines and Schedule 5 Poisons (SUSMP) Schedule 6

National regulations

tational rogalations		
Chemical name	French RG number	
Sodium metabisulfite USP	RG 66	
7681-57-4		

Germany

Chemical Prohibition Ordinance (ChemVerbotsV)

Not applicable

TRGS 905 Not applicable

Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018 Not applicable Storage of Hazardous Material Not applicable WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20 Not applicable Not applicable Major Accidents Ordinance SR 814.012

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Sodium metabisulfite USP 7681-57-4	75	-

Product Name Gentamicin Sulfate Injection, USP 80 mg/2 mL (40 mg/mL as Gentamicin) (Hospira, Inc.)

Revision date 13-Jun-2025 Version 5

Sodium hydroxide 1310-73-2	75	-
+ Hydrochloric Acid 7647-01-0	75	-

Persistent Organic Pollutants

Not applicable

Chemical name	Lower-tier requirements (tons)	Upper-tier requirements (tons)
+ Hydrochloric Acid	25	250
7647-01-0		

Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

Chemical name	Biocidal Products Regulation (EU) No 528/2012 (BPR)
Sodium metabisulfite USP	Product-type 9: Fiber, leather, rubber and polymerized
7681-57-4	materials preservatives
+ Hydrochloric Acid	Product-type 2: Disinfectants and algaecides not intended
7647-01-0	for direct application to humans or animals

Explosives Precursors Marketing and Use (2019/1148)

Not applicable

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

KECL - Korean Existing Chemicals Inventory

PICCS - Philippines Inventory of Chemicals and Chemical Substances

AICS - Australian Inventory of Chemical Substances

NZIoC - New Zealand Inventory of Chemicals

TCSI - Taiwan Chemical Substance Inventory

15.2. Chemical safety assessment

No information available **Chemical Safety Report**

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H314 - Causes severe skin burns and eye damage H302 - Harmful if swallowed H318 - Causes serious eye damage H360D - May damage the unborn child H317 - May cause an allergic skin reaction H331 - Toxic if inhaled

Publicly available toxicity information. Safety data sheets for individual ingredients. **Data Sources:**

PZ03380

Page 15 / 16

Product Name Gentamicin Sulfate Injection, USP 80 mg/2 mL (40 mg/mL as Gentamicin) (Hospira, Inc.) Revision date 13-Jun-2025

vision date 13-Jun-2025 Version 5

Reason for revision Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on

Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological

Page 16 / 16

Information.

Revision date 13-Jun-2025

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.